Merck paying up to $208M to buy UB cancer research startup
Abceutics Inc., a startup preclinical-stage biopharmaceutical company spun out of a laboratory at the University at Buffalo, is being purchased as part of an up-to-$208 million agreement with biopharmaceutical giant